Clear cell renal cell carcinoma accounts for roughly 70 percent of all kidney cancer diagnoses, presenting a severe clinical challenge characterized by profound intratumoural heterogeneity and an aggressive propensity for haematogenous metastasis. In a detailed study combining large-scale single-cell transcriptomics with cellular and animal experiments, researchers identified the heparin-binding growth factor Midkine as a central driver of metastatic progression and dismal patient survival. Examining primary tumour specimens, the team discovered that clear cell renal lesions from patients with metastatic disease harbor distinct cellular states defined by elevated Midkine expression within malignant epithelial lineages. Rather than arising through isolated transcriptional fluctuations, this upregulation is driven by an epitranscriptomic regulatory axis. Specifically, the RNA methyltransferase subunit WTAP promotes N6-methyladenosine modification on Midkine messenger RNA, facilitating recognition by the cytoplasmic reader protein YTHDF1. This binding stabilizes the transcript, elevates Midkine protein production, and activates both tumour-intrinsic invasion and microenvironmental immunosuppression.
The clinical realities of renal cell carcinoma highlight the urgent requirement for discovering molecular determinants that distinguish localized primary tumours from those prone to systemic dissemination. In 2026, the United States recorded an estimated 80,450 new kidney cancer diagnoses alongside 15,160 disease-related fatalities. Because clear cell renal cell carcinoma frequently develops without noticeable symptoms, diagnosis is routinely delayed, resulting in metastatic presentation in approximately one-third of newly diagnosed patients. Although targeted therapeutic regimens have improved clinical management, the prognosis for metastatic disease remains exceptionally poor, with five-year overall survival hovering at approximately 17 percent. Modern immune checkpoint inhibitors have introduced therapeutic benefit, yet their combination with targeted agents can exacerbate complications such as severe proteinuria. Furthermore, clear cell renal cell carcinoma exhibits an immunological paradox: while cytotoxic CD8-positive T-cell infiltration normally signals favourable prognosis across most solid tumours, its presence in clear cell renal lesions correlates with significantly shortened patient survival.
To decipher the cellular dynamics underlying metastatic capability, investigators assembled a cross-cohort transcriptomic atlas by integrating four independent single-cell RNA sequencing datasets. This analytical framework integrated three established public datasets—accession codes GSE159115, SRZ190804, and Single Cell Portal repository SCP1288—with newly sequenced primary tumour tissues obtained from two non-metastatic patients treated at the Affiliated Hospital of Qingdao University. Preprocessing and batch correction performed through the Seurat platform utilizing the SCTransform normalization workflow yielded an integrated dataset of 191,564 single cells across 46 tissue samples derived from 23 patients, encompassing 7,844 cells from the institutional cohort. Canonical lineage marker expression partitioned the integrated microenvironment into seven major cell categories: T lymphocytes, B lymphocytes, plasma cells, myeloid lineages, endothelial cells, stromal fibroblasts, and normal or neoplastic nephron cells. Immune composition varied substantially across clinical states, with untreated metastatic specimens showing increased plasma cell infiltration alongside distinct subpopulations of exhausted CD8-positive T cells and regulatory lymphocytes.
To prevent tissue-specific confounding biases, all subsequent analytical workflows focused exclusively on primary tumour tissues and matched normal renal parenchyma. Meticulous clustering of 35,837 epithelial nephron cells identified seven discrete lineages, spanning glomeruli, type A and B intercalated cells, loop of Henle cells, principal cells, proximal tubules, and CA9-positive nephrons. Computational inferCNV analysis confirmed that CA9-positive cells harboured widespread chromosomal copy number variations compared to non-malignant reference cells, verifying their neoplastic origin. Neoplastic cells localized predominantly to two tubular lineages: proximal tubule (PT) and differentiated proximal tubule 1 (dPT1). Notably, metastatic patients exhibited a significantly higher proportion of RBP5-high proximal tubule cells compared to non-metastatic cohorts. Although PT and dPT1 branches exhibited differential baseline gene expression in healthy tissue associated with physiological hypoxic responses, within neoplastic environments their transcriptional programmes diverged sharply. Neoplastic PT cells upregulated pathways governing metabolic adaptation and PD-1 signalling, whereas dPT1 cells upregulated programmes linked to cell-cell adhesion, interferon signalling, and interleukin-4 and interleukin-13 cascades.
Comparative differential expression analysis across normal tissue, non-metastatic tumours, and metastatic lesions—excluding immunotherapy-treated cases to prevent treatment-associated bias—demonstrated that metastatic primary tumours prominently upregulate pathways governing cellular proliferation, metabolic reprogramming, and epithelial-to-mesenchymal transition. Univariate and multivariate Cox proportional hazards regression models revealed that Midkine and SOCS3 served as statistically independent prognostic biomarkers capable of stratifying patient survival. Inferred copy number analysis and expression profiling revealed that Midkine was significantly amplified and elevated in metastatic tumours, particularly across both PT and dPT1 lineages. Immunohistochemical staining confirmed intense Midkine protein signals in clinical metastatic specimens. Mapping cells against foundational TCGA clear cell renal carcinoma subgroups (m1 through m4) showed that while the m4 subtype predominated overall, the favourable m1 subgroup occurred more frequently in non-metastatic disease, whereas the aggressive m3 subgroup appeared predominantly in metastatic cases. Midkine was markedly overexpressed within m3 tumours and aggressive metastatic m4 subsets, directly linking its expression to advanced stage and decreased survival.
Investigating cell-cell communication networks using CellPhoneDB, CellChat, and iTALK computational pipelines demonstrated marked microenvironmental remodelling in metastatic tumours. Malignant dPT1 cells functioned as central signalling senders, engaging in dense ligand-receptor communication with tumour-associated macrophages, including C1QC-positive and ISG15-positive subsets. In localized non-metastatic tumours, macrophage communication was dominated by major histocompatibility complex class II molecules, such as HLA-CD4 pairs, and featured elevated transcriptional scores for antigen presentation. Conversely, metastatic lesions exhibited heightened interactions mediated by macrophage migration inhibitory factor, type I collagen alpha 1, and tumour-secreted Midkine. Macrophages residing in metastatic environments displayed significantly elevated M2 polarization scores alongside increased pro-angiogenic transcriptional profiles and enriched growth factor signalling. These single-cell observations indicate that clear cell renal carcinoma cells actively secrete Midkine to recruit circulating monocytic precursors into the tumour parenchyma and steer their functional maturation toward an immunosuppressive, pro-tumourigenic M2-like macrophage phenotype that facilitates matrix remodelling and tumour vascularization.
Downstream analysis of macrophage communication revealed how this Midkine-driven myeloid reprogramming directly suppresses cytotoxic immune responses within metastatic clear cell renal carcinoma. While macrophage-to-T-cell communication in localized disease was driven by co-stimulatory molecules including CD80 and tumor necrosis factor superfamily ligands, metastatic interactions were heavily dominated by immunosuppressive ligand-receptor pairs. Metastatic macrophages selectively interacted with CD8-positive T lymphocytes through upregulated VCAM1 and SPP1 expression, alongside the TIGIT immune checkpoint and the inhibitory CD24-SIGLEC10 axis. Gene set enrichment analysis of differentially expressed genes in CD8-positive T cells from metastatic patients revealed marked upregulation of chemokine receptor pathways and immunosuppressive interleukin-10 signalling cascades. Because elevated SPP1 expression in tumour-associated macrophages correlates with aggressive disease and interleukin-10 potently inhibits T-cell effector functions, these findings define an integrated immunosuppressive axis. Tumour-derived Midkine recruits and polarizes M2-like macrophages, which deploy SPP1, CD24, and immunosuppressive cytokine networks to impair cytotoxic CD8-positive T cells, explaining the failure of antitumour immunity.
To experimentally confirm the biological functions of Midkine, the researchers evaluated human clear cell renal cell carcinoma cell lines Caki-1 and 786-O alongside non-cancerous human renal proximal tubular epithelial HK-2 cells. Quantitative real-time PCR and Western blotting confirmed that Midkine mRNA and protein levels were markedly elevated in both malignant lines relative to normal controls. Lentivirus-mediated knockdown using small interfering RNA (Lv-si-MDK) achieved robust Midkine suppression. EdU proliferation assays demonstrated that Midkine depletion significantly reduced cell division rates, while annexin flow cytometry revealed a corresponding increase in apoptotic cell death. Furthermore, transwell migration and Matrigel invasion assays, combined with scratch wound-healing measurements, demonstrated that Midkine silencing dramatically impaired the motility and invasive capacity of renal cancer cells. At the molecular level, Midkine knockdown increased the expression of the epithelial junction protein E-cadherin while substantially suppressing mesenchymal markers N-cadherin and Vimentin, confirming that Midkine directly drives epithelial-to-mesenchymal transition in clear cell renal carcinoma.
Exploring the upstream mechanism responsible for Midkine overexpression, researchers investigated post-transcriptional RNA modification, focusing on N6-methyladenosine (m6A) machinery. SRAMP database analysis predicted multiple m6A modification motifs on Midkine mRNA, identifying a high-confidence consensus site between positions 1800 and 2000 base pairs, peaking at position 1826. Knockdown of WTAP, a key regulatory subunit of the core m6A methyltransferase complex, significantly reduced total global m6A abundance in Caki-1 cells and suppressed Midkine-specific m6A modification in methylated RNA immunoprecipitation (MeRIP) assays. Dual-luciferase reporter assays demonstrated that WTAP silencing reduced luciferase reporter activity driven by wild-type Midkine mRNA, whereas YTHDF1 overexpression enhanced reporter activity, effects that were completely lost when the predicted m6A site was mutated. RNA immunoprecipitation assays confirmed direct physical binding of WTAP and YTHDF1 to endogenous Midkine transcripts. In actinomycin D decay experiments, WTAP depletion accelerated Midkine mRNA degradation, whereas YTHDF1 overexpression reversed this instability, demonstrating that WTAP-dependent m6A modification promotes Midkine expression by enabling YTHDF1 to stabilize its messenger RNA.
The physiological importance of the WTAP-YTHDF1-Midkine regulatory axis was confirmed using BALB/c nude mouse xenograft and lung metastasis models established with Caki-1 cells. In subcutaneous xenografts, WTAP knockdown slowed tumour growth, reducing final tumour volumes and weights, whereas concurrent Midkine overexpression completely rescued tumourigenic growth. Similarly, in a tail-vein pulmonary metastasis model, WTAP silencing markedly reduced metastatic lung nodule frequency and cellular density, decreased proliferation marker Ki-67, increased apoptosis executioner Caspase-3, restored E-cadherin, and suppressed N-cadherin and Vimentin, with Midkine re-expression reversing each change. Despite these compelling discoveries, the authors outlined key study limitations, including a small institutional metastatic cohort, reliance on retrospective public single-cell datasets, and computationally inferred ligand-receptor pairings requiring further testing. Moreover, mRNA stability was evaluated solely via actinomycin D assays, and in vivo validation was restricted to one cell line. Nevertheless, this work elucidates how WTAP-mediated m6A modification elevates Midkine to coordinate cancer cell invasion and microenvironmental immunosuppression, highlighting Midkine as a valuable prognostic biomarker and promising therapeutic candidate in metastatic renal cancer.
Subject of Research: Clear cell renal cell carcinoma metastasis mechanisms and tumour microenvironment remodelling
Article Title: WTAP/m6A/YTHDF1-mediated upregulation of Midkine expression drives clear cell renal cell carcinoma metastasis: insights from single-cell sequencing
Article References: Yin, X., Li, Z., Yang, H., Zhao, K., Zhu, G., Zhang, Z., Li, X., Wang, Y., Zheng, X., & Wang, K. (2026). WTAP/m6A/YTHDF1-mediated upregulation of Midkine expression drives clear cell renal cell carcinoma metastasis: insights from single-cell sequencing. Molecular Biomedicine, 7(1), Article 257. https://doi.org/10.1186/s43556-026-00665-4
Image Credits: AI Generated
DOI: 10.1186/s43556-026-00665-4
Keywords: clear cell renal cell carcinoma, single-cell RNA sequencing, Midkine, WTAP, m6A methylation, YTHDF1, tumour microenvironment, metastasis, macrophage polarization, CD8+ T cells, epithelial-mesenchymal transition, renal cancer, Caki-1 cells, 786-O cells, xenograft models, SPP1, gene expression, cancer biomarkers
